uk

A surgical centre for NHS Scotland North, serving Grampian and the islands; a Precision-Panc and ginisortamab trial site.

The East of England's HPB specialist centre, with liver transplantation; a BILCAP site and a site of the UK biliary microbiome study.

In England the offer has four named parts: an assessment of what you need and a plan written with you, information and support about living well, a summary of your treatment sent to you and your GP, and a review with your GP. Follow-up is increasingly not a routine clinic appointment but a pathway you manage yourself, with tests at set intervals and a route back in.

The largest randomised trial ever run inside a screening programme: nearly four million women cluster-randomised to an extra mammogram below 50 or above 70, and the reason the programme's age range has not moved.

The Newcastle oncologist who led the NHS England pilot that put a blood test for lung cancer mutations into the diagnostic pathway, and who co-leads the CONCORDE radiotherapy platform.

The UK's only charity dedicated to cholangiocarcinoma and the other biliary tract cancers: patient information, a list of UK centres with expertise, research grants, an annual conference and a nurse study day.

The Glasgow surgeon-scientist who mapped the genomic subtypes of pancreatic cancer and built Precision-Panc, the UK programme that profiled tumours to route patients into the PRIMUS trials.

Medical oncologist who co-chairs the breast disease group at The Christie, the Manchester cancer centre that is a site of the PHOENIX, PARTNER and ASCENT-05 trials for triple-negative disease.

The UK stem cell register, founded in 1974, and the charity behind the clinical nurse specialists who look after transplant patients in NHS centres.

Northern Ireland's single HPB cancer service, within the Belfast Trust; systemic treatment at the Northern Ireland Cancer Centre.

The British trial that asked, without enthusiasm or spin, what chemotherapy is actually worth in lung cancer, and found it worth nine weeks in advanced disease and nothing at all after surgery or radiotherapy.

Liverpool molecular scientist behind the EUROPAC registry's laboratory work and the biomarker analyses of the ESPAC trial samples.

The UK's blood cancer research charity and support line, covering lymphoma alongside leukaemia and myeloma.

The UK's bowel cancer charity: information and an email service answered by colorectal nurses, the Never Too Young campaign for younger patients, and the policy work that pushes the NHS on screening, Lynch syndrome testing and emergency diagnosis.

The UK medical research charity for bowel disease: small proof-of-concept grants and PhDs in bowel cancer and inflammatory bowel disease, with patients on its review panels.

The UK's breast cancer research and support charity: a free nurse helpline, the Someone Like Me peer service, Moving Forward courses, an online forum and patient information on triple-negative disease, alongside funding of the Toby Robins Research Centre at the ICR.

The professional body that writes the UK's skin cancer service standards and, because these cancers have almost no charity of their own, also writes most of the patient information a person with a basal cell carcinoma will be handed.

Britain's own survivor cohort, built on national registration rather than on hospital volunteers, which is why it can follow people for half a century and count deaths that nobody reported. Its central finding is that what kills survivors changes with time: recurrence early, second cancers and heart disease late.

An NHS England fund that pays for promising cancer drugs while more evidence is collected, born in 2010 as a political fix for drugs NICE had refused and rebuilt in 2016 into a time-limited managed access scheme with a fixed budget.

The UCL urologist who has spent her career on the two questions that decide whether a man with prostate cancer is harmed by being diagnosed: who needs a biopsy, and who needs treating at all.

The HPB specialist centre for Hull and East Yorkshire, one of the 23 English surgical hubs in the National Pancreatic Cancer Audit and a Precision-Panc site.

A British radiotherapy schedule, invented at Mount Vernon, that squeezed a six-week course into twelve days and cut the risk of death by about a quarter.

Liverpool pancreatic surgeon who leads EUROPAC, the UK registry and surveillance programme for families with inherited pancreatic cancer risk and hereditary pancreatitis.

Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.

Liverpool medical oncologist, second author of ESPAC-4 and co-lead of ESPAC5, who directs the Liverpool Experimental Cancer Medicine Centre and leads the national GIRFT review of pancreatic cancer services.

The Nottingham chest physician who chairs the UK clinical expert group for lung cancer and advises the National Screening Committee: the person whose job it is to turn the screening evidence into an NHS service.

The Leeds clinical oncologist who led CR07, the trial that made short-course radiotherapy before surgery the standard for rectal cancer, and who now works on preserving the rectum instead of removing it.

Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not.

The HPB specialist centre for the South West Peninsula (Devon, Cornwall and the Isles of Scilly); a BILCAP site.

The Birmingham surgeon who chairs FOxTROT and runs the surgical trials programme that tests how bowel cancer operations are done, not just which drugs come with them.

First author of POSH, the UK prospective cohort of young-onset breast cancer that showed germline BRCA carriers did no worse than non-carriers, and the ones with triple-negative disease did better in the first two years.

The UK's registry and screening programme for families with inherited pancreatic cancer risk, run from Liverpool since 2000; its 2026 outcomes paper shows risk-stratified surveillance finds four times more actionable lesions.

The UK trial that showed giving some chemotherapy before the operation for colon cancer shrinks the tumour, leaves cleaner margins and cuts the chance of the cancer coming back.

The Birmingham oncologist who ran the National Lung Matrix Trial, the largest umbrella trial in lung cancer, and published the honest answer: most drug-biomarker pairs did not work.

The HPB surgical centre for the West of Scotland Cancer Network; chemotherapy and immunotherapy are given at the Beatson.

Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.

Liver surgeon at Aintree who co-wrote the BSG cholangiocarcinoma guideline and is a co-author of the UK-wide CAPBIL studies of gallbladder cancer surgery; a past president of the British Association of Surgical Oncology.

Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up.

The Nottingham epidemiologist who founded British evidence-based dermatology and ran the trial that answered whether a cream can replace surgery for the commonest cancer there is.

A Royal Marsden gastrointestinal oncologist who has shaped UK colorectal and upper gastrointestinal trials and who works on the blood test for residual disease after bowel surgery.

The UK-led prevention trial that showed five years of tamoxifen keeps preventing breast cancer for at least twenty years, and the reason NICE tells the NHS to offer it to premenopausal women at high familial risk.

The trial that made anastrozole a prevention drug, halving breast cancer in postmenopausal women at high risk and, with a licence granted in 2023, putting a generic tablet on the NHS prevention pathway.

The UK's post-Brexit scheme, launched in 2021 and refreshed in 2025, that brings the medicines regulator, NICE and the NHS together early in a drug's development so that licensing and the decision to pay for it can happen close together.

The British trial testing whether the immunotherapy that works for advanced squamous cell carcinoma also works, first line, for the advanced basal cell carcinomas NICE refused to fund a hedgehog inhibitor for.

A fund launched in 2022 that does for non-cancer medicines what the Cancer Drugs Fund does for cancer: pays for a promising but uncertain drug for a limited period while evidence is gathered, with the same budget of 340 million pounds.

Chief investigator of PARTNER, the UK trial of neoadjuvant olaparib with platinum chemotherapy in triple-negative and BRCA-associated breast cancer, run from Addenbrooke's across 23 NHS sites (30 on the ClinicalTrials.gov record).

The Bristol social scientist who worked out how to recruit men into a trial that asked them to accept a coin toss between surgery, radiotherapy and doing nothing, and then measured honestly what each did to their lives.

Senior author of the UK's two standard-setting biliary trials, ABC-02 and BILCAP, chief investigator of ABC-06, and UK lead of the first-line precision medicine trial SAFIR-ABC10.

The Newcastle geneticist whose CAPP2 trial showed that two years of aspirin cuts bowel cancer in people born with Lynch syndrome, a result that still shapes NHS advice.

The Liverpool scientist behind the UK Lung Cancer Screening trial and the Liverpool Lung Project risk model, which is one of the two rules the NHS uses to decide who is invited for a scan.

Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.

One of London's specialist liver and hepatobiliary centres, with a liver transplant programme; listed by the national audit as an HPB specialist centre and by AMMF as a centre with cholangiocarcinoma expertise.

The specialist heart and chest hospital for Cheshire and Merseyside, which calls its thoracic service one of the largest and busiest specialist thoracic surgical units in the country.

The North Western Hepatobiliary Centre at Aintree, serving Merseyside, Cheshire, North Wales and the Isle of Man; HPB surgeon Hassan Malik co-wrote the BSG cholangiocarcinoma guideline.

The British trial that tested a cheap, staged alternative to scanning everyone, and found it did not work: more than half the cancers never showed up in the sputum at all.

The United Kingdom's only charity dedicated to lymphoma: a freephone helpline, support groups, a buddy scheme, a lymphoma trials database and a seat at the table when NICE and the Scottish Medicines Consortium appraise a lymphoma medicine.

Leads biliary tract cancer trials at The Christie, the Manchester centre behind the ABC trial series, and is a member of the international biliary trial collaborations.

Greater Manchester's HPB surgical unit; works with The Christie, where the region's biliary oncology and the ABC trial series are based.

Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.

The Leeds oncologist behind the FOCUS trials, which asked how best to sequence chemotherapy for advanced bowel cancer, and a leader of FOxTROT, which moved chemotherapy before surgery in colon cancer.